Abstract:
A computer-implemented process for controlling a vehicle interior includes detecting a previously defined situation that relates to an undesirable environmental condition of the vehicle interior, and assessing both a risk level and an urgency level, based on a vehicle sensor input. The process also includes generating a vehicle command based upon the detected previously defined situation, the assessed risk level, and assessed urgency level, and executing the generated vehicle command to control at least one of an engine, a window, and a heating, ventilation and air conditioning (HVAC) unit to modify an environmental condition of the vehicle interior.
Abstract:
A computer-implemented process for controlling a vehicle interior includes detecting a previously defined situation that relates to an undesirable environmental condition of the vehicle interior, and assessing both a risk level and an urgency level, based on a vehicle sensor input. The process also includes generating a vehicle command based upon the detected previously defined situation, the assessed risk level, and assessed urgency level, and executing the generated vehicle command to control at least one of an engine, a window, and a heating, ventilation and air conditioning (HVAC) unit to modify an environmental condition of the vehicle interior.
Abstract:
A composition includes polydatin and solvent for dissolving the polydatin, wherein the solvent comprises alcohol in a range between 40 and 95% by volume, propanediol in a range between 0 and 60% by volume, and water in remaining volume. The concentration of the polydatin must be at least 6 mg/ml. The composition has good stability in cold preservation. The composition is in a pharmaceutically acceptable administrative form selected from the group consisting of an intravenous injection, and intramuscular injection, an oral administration, a spray solution, and an aerosol form.
Abstract:
The present invention provides new use of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside. 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside has efficacies of anti-myocardial ischemia by intravenous injection and/or oral administration. It is advantageous that 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside as anti-myocardial ischemia drug is used to prepare the medicine for treating and/or preventing ischemic heart disease.
Abstract:
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
Abstract:
Systems, methods and computer program products for storing data from multiple clients in a database include a Multi-thread Shared Memory message Queue Buffer (MSMQB) that includes multiple First-In First-Out (FIFO) queues, a respective one of which is associated with a respective one of the clients. The MSMQB is configured to store sequential bursts of data records that are received from the clients in the associated FIFO queues. A Semi-Merge Sort Module (SMSM) is configured to sort the sequential bursts in the FIFO queues based on the primary key of at least one selected record but not every record, to produce a semi-sorted record stream for serially stored in the database.
Abstract:
The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand that compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.
Abstract:
This invention relates generally to cyclic polypeptides comprising a thioether linkage and methods for their preparation. More particularly, this invention relates to halogenated polypeptides having at least one haloalanine-like amino acid, and methods for their preparation which involve converting the hydroxyl group (i.e., --OH) of a serine-like amino acid to a halo group (i.e., --X where X is Cl, Br, or I) with the aid of a phosphorus-based halogenation reagent such as a triphenylphosphine dihalide (i.e., (C.sub.6 H.sub.5).sub.3 PX.sub.2, wherein X is Cl, Br, or I), a triphenylphosphite dihalide (i.e., (C.sub.6 H.sub.5 O).sub.3 PX.sub.2, wherein X is Cl, Br, or I), or a mixture of triphenylphosphine or triphenylphosphite with a halohydrocarbon (i.e., "halo-conversion"). This invention also relates to cyclic polypeptides having at least one polypeptide loop comprising a thioether linkage, and methods for their preparation which employ halogenated polypeptides and which involve intramolecular alkylation of the thiol group of a cysteine-like amino acid by the halo group of a haloalanine-like amino acid under suitable basic conditions to form a thioether linkage (i.e., "cyclization").